Sol-Gel Investor Relations Material
Latest events
M&A Announcement
Sol-Gel
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sol-Gel Technologies Ltd
Access all reports
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. The company offers Phase 5 (clobex), a prescription liquid medication designed to selectively target specific classes of dendritic cells that initiate the immune response. Its smevetch is a topical compounded drug that contains tacrolimus and dexamethasone. The company was formerly known as Silex Platform Limited and changed its name to Sol-Gel Technologies Ltd. in June 2010. Sol-Gel Technologies Ltd. is based in London, the United Kingdom.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SLGL
Country
🇺🇸 United States